Lexaria Bioscience (LEXX) Gains from Investment Securities (2014 - 2026)

Lexaria Bioscience has disclosed Gains from Investment Securities across 13 years of filings, most recently posting $1.5 million for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $1.5 million, up 939.46% year-over-year; the trailing twelve-month figure through Feb 2026 was $1.5 million (up 939.46% YoY), and the FY2025 annual result was $1.5 million, up 57.09% from the prior year.
• Gains from Investment Securities came in at $1.5 million for Q1 2026 at Lexaria Bioscience, down from $1.5 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.5 million in Q4 2025 to a low of $6818.0 in Q4 2024.
• The 5-year median for Gains from Investment Securities is $85000.0 (2023), against an average of $320348.9.
• Across the five-year window, Gains from Investment Securities plunged 93.26% in 2024 and soared 21672.29% in 2025, its largest moves.
• Lexaria Bioscience's Gains from Investment Securities stood at $44600.0 in 2022, then jumped by 90.58% to $85000.0 in 2023, then sank by 91.98% to $6818.0 in 2024, then jumped by 21672.29% to $1.5 million in 2025, then declined by 0.57% to $1.5 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.5 million (Q1 2026), $1.5 million (Q4 2025), and $7199.0 (Q3 2025), per Business Quant data.